The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine
Abstract Despite the importance of immunity against neuraminidase (NA), NA content and immunogenicity are neglected in current influenza vaccines. To address this, a recombinant N1/N2 NA vaccine (NAV) was developed. Stability assays were used to determine optimal temperature and buffer conditions fo...
Guardado en:
Autores principales: | , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e4321783a19a4370b86945991fe73acd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:e4321783a19a4370b86945991fe73acd |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:e4321783a19a4370b86945991fe73acd2021-12-02T14:17:31ZThe effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine10.1038/s41541-021-00310-x2059-0105https://doaj.org/article/e4321783a19a4370b86945991fe73acd2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00310-xhttps://doaj.org/toc/2059-0105Abstract Despite the importance of immunity against neuraminidase (NA), NA content and immunogenicity are neglected in current influenza vaccines. To address this, a recombinant N1/N2 NA vaccine (NAV) was developed. Stability assays were used to determine optimal temperature and buffer conditions for vaccine storage. The effect of divalent cation-related enhancement of NA stability and activity on N1 and N2 immunogenicity and efficacy against viral challenge was assessed. Differences in activity between N1 and N2 and cation-related activity enhancement did not translate into differences in immunogenicity or efficacy. NAV-vaccinated mice showed robust antibody titers against N1 and N2, and after challenge with influenza A (H1N1) virus, decreased viral titers and decreased antiviral and inflammatory responses by transcriptomic analysis. These findings provide guidance for optimal storage and assessment of NA-based vaccines and confirm the importance of NA in influenza vaccination strategies in attenuating viral replication and limiting inflammatory responses necessary to clear infection.Luca T. GiurgeaJae-Keun ParkKathie-Anne WaltersKelsey ScherlerAdriana Cervantes-MedinaAshley FreemanLuz Angela RosasJohn C. KashJeffery K. TaubenbergerMatthew J. MemoliNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-7 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Luca T. Giurgea Jae-Keun Park Kathie-Anne Walters Kelsey Scherler Adriana Cervantes-Medina Ashley Freeman Luz Angela Rosas John C. Kash Jeffery K. Taubenberger Matthew J. Memoli The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine |
description |
Abstract Despite the importance of immunity against neuraminidase (NA), NA content and immunogenicity are neglected in current influenza vaccines. To address this, a recombinant N1/N2 NA vaccine (NAV) was developed. Stability assays were used to determine optimal temperature and buffer conditions for vaccine storage. The effect of divalent cation-related enhancement of NA stability and activity on N1 and N2 immunogenicity and efficacy against viral challenge was assessed. Differences in activity between N1 and N2 and cation-related activity enhancement did not translate into differences in immunogenicity or efficacy. NAV-vaccinated mice showed robust antibody titers against N1 and N2, and after challenge with influenza A (H1N1) virus, decreased viral titers and decreased antiviral and inflammatory responses by transcriptomic analysis. These findings provide guidance for optimal storage and assessment of NA-based vaccines and confirm the importance of NA in influenza vaccination strategies in attenuating viral replication and limiting inflammatory responses necessary to clear infection. |
format |
article |
author |
Luca T. Giurgea Jae-Keun Park Kathie-Anne Walters Kelsey Scherler Adriana Cervantes-Medina Ashley Freeman Luz Angela Rosas John C. Kash Jeffery K. Taubenberger Matthew J. Memoli |
author_facet |
Luca T. Giurgea Jae-Keun Park Kathie-Anne Walters Kelsey Scherler Adriana Cervantes-Medina Ashley Freeman Luz Angela Rosas John C. Kash Jeffery K. Taubenberger Matthew J. Memoli |
author_sort |
Luca T. Giurgea |
title |
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine |
title_short |
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine |
title_full |
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine |
title_fullStr |
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine |
title_full_unstemmed |
The effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant N1/N2 neuraminidase vaccine |
title_sort |
effect of calcium and magnesium on activity, immunogenicity, and efficacy of a recombinant n1/n2 neuraminidase vaccine |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/e4321783a19a4370b86945991fe73acd |
work_keys_str_mv |
AT lucatgiurgea theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT jaekeunpark theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT kathieannewalters theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT kelseyscherler theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT adrianacervantesmedina theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT ashleyfreeman theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT luzangelarosas theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT johnckash theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT jefferyktaubenberger theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT matthewjmemoli theeffectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT lucatgiurgea effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT jaekeunpark effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT kathieannewalters effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT kelseyscherler effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT adrianacervantesmedina effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT ashleyfreeman effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT luzangelarosas effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT johnckash effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT jefferyktaubenberger effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine AT matthewjmemoli effectofcalciumandmagnesiumonactivityimmunogenicityandefficacyofarecombinantn1n2neuraminidasevaccine |
_version_ |
1718391639467098112 |